Two patients with advanced multiple myeloma were treated with oral low
-dose cyclosporin A, one without other therapy and one in conjunction
with chemotherapy to which the patient had been previously unresponsiv
e. Both patients had objective laboratory and clinical responses. In t
he patient treated with cyclosporin A alone, decreasing serum IL-6 and
beta-2-microglobulin levels fell as the clinical response evolved. Cy
closporin A deserves further evaluation in the therapy of multiple mye
loma.